Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT02716805
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02643303
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
- Conditions
- Interventions
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 53
- Registration Number
- NCT02639026
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT02592551
- Locations
- 🇺🇸
Baylor St Lukes, Houston, Texas, United States
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT02586987
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 50
- Registration Number
- NCT02571725
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States
🇺🇸University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02563925
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02549651
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 153
- Registration Number
- NCT02537418
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 433
- Registration Number
- NCT02519348
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.